Glepaglutide, a Long-acting Glucagon-like Peptide-2 Analog, Reduces Parenteral Support in Patients with Short Bowel Syndrome: a Phase 3, Randomized, Controlled Trial,Gastroenterology

当前位置： X-MOL 学术 › Gastroenterology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Glepaglutide, a Long-acting Glucagon-like Peptide-2 Analog, Reduces Parenteral Support in Patients with Short Bowel Syndrome: a Phase 3, Randomized, Controlled Trial
Gastroenterology ( IF 25.7 ) Pub Date : 2024-12-19 , DOI: 10.1053/j.gastro.2024.11.023
Palle B. Jeppesen, Tim Vanuytsel, Sukanya Subramanian, Francisca Joly, Geert Wanten, Georg Lamprecht, Marek Kunecki, Farooq Rahman, Thor S.S. Nielsen, Mark Berner-Hansen, Ulrich-Frank Pape, David F. Mercer

BACKGROUND AND AIMS

Glepaglutide is a long-acting GLP-2 analog developed to improve intestinal absorption in short bowel syndrome (SBS) patients. We conducted a trial to establish efficacy and safety of glepaglutide in reducing parenteral support (PS) needs in SBS patients with intestinal failure (IF).

METHODS

In an international, placebo-controlled, randomized, parallel-group, double-blind, phase 3 trial, SBS-IF patients requiring PS ≥3 days/week were randomized 1:1:1 to 24 weeks of glepaglutide 10 mg twice-weekly (TW) or once-weekly (OW), or placebo. PS volume was equivalently reduced if average urine volume of a 48-hour balance period exceeded baseline values by >10%.

RESULTS

106 patients were randomized and dosed. Glepaglutide TW significantly reduced weekly PS volumes from baseline to week 24 versus placebo (mean change of −5.13 vs. −2.85 L/week; P = .0039; primary endpoint). Results were similar across major anatomical subgroups. Glepaglutide TW was also superior to placebo for key secondary endpoints of proportion of patients achieving clinical response defined as ≥20% PS volume reduction from baseline to weeks 20 and 24 (65.7% vs. 38.9%; P = .0243), and patients achieving a reduction in days on PS ≥1 day/week from baseline to week 24 (51.4% vs. 19.4%; P = .0043). Complete PS weaning (“enteral autonomy”) was achieved for 5 patients (14%) receiving glepaglutide TW versus 0 for placebo patients. No statistically significant differences were shown for glepaglutide OW versus placebo for primary or key secondary endpoints. Significant glepaglutide benefits on patient-reported outcome (Patient Global Impression of Change) were shown. Glepaglutide was assessed to be safe and well tolerated.